NO973529D0 - Anvendelse av 5'-substituerte nukleosider for å hemme resistensdannelse ved cytostatisk behandling og legemidler inneholdende slike nukleosider - Google Patents

Anvendelse av 5'-substituerte nukleosider for å hemme resistensdannelse ved cytostatisk behandling og legemidler inneholdende slike nukleosider

Info

Publication number
NO973529D0
NO973529D0 NO973529A NO973529A NO973529D0 NO 973529 D0 NO973529 D0 NO 973529D0 NO 973529 A NO973529 A NO 973529A NO 973529 A NO973529 A NO 973529A NO 973529 D0 NO973529 D0 NO 973529D0
Authority
NO
Norway
Prior art keywords
nucleosides
cytostatic
bvdu
cytostatic treatment
resistance
Prior art date
Application number
NO973529A
Other languages
English (en)
Other versions
NO973529L (no
NO315258B1 (no
Inventor
Rudolf Fahrig
Angela Steinkampzucht
Original Assignee
Fraunhofer Ges Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545892A external-priority patent/DE19545892A1/de
Application filed by Fraunhofer Ges Forschung filed Critical Fraunhofer Ges Forschung
Publication of NO973529D0 publication Critical patent/NO973529D0/no
Publication of NO973529L publication Critical patent/NO973529L/no
Publication of NO315258B1 publication Critical patent/NO315258B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NO19973529A 1995-02-01 1997-07-31 Anvendelse av 5'-substituerte nukleosider NO315258B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19503152 1995-02-01
DE19545892A DE19545892A1 (de) 1995-12-08 1995-12-08 Verwendung von (E)-5-(2-Bromovinyl-)-2'-deoxyuridine (BVDU) zur Resistenzbildung bei der Zytostatikabehandlung und Arzneimittel, enthaltend BVDU
PCT/DE1996/000169 WO1996023506A1 (de) 1995-02-01 1996-01-31 Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside

Publications (3)

Publication Number Publication Date
NO973529D0 true NO973529D0 (no) 1997-07-31
NO973529L NO973529L (no) 1997-10-01
NO315258B1 NO315258B1 (no) 2003-08-11

Family

ID=26012025

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19973529A NO315258B1 (no) 1995-02-01 1997-07-31 Anvendelse av 5'-substituerte nukleosider

Country Status (12)

Country Link
US (1) US6589941B1 (no)
EP (1) EP0806956B1 (no)
JP (1) JPH11502515A (no)
KR (1) KR100330602B1 (no)
AT (1) ATE222765T1 (no)
BR (1) BR9607109A (no)
DE (1) DE59609590D1 (no)
DK (1) DK0806956T3 (no)
ES (1) ES2180730T3 (no)
NO (1) NO315258B1 (no)
PT (1) PT806956E (no)
WO (1) WO1996023506A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE413881T1 (de) 1997-08-08 2008-11-15 Celmed Oncology Usa Inc Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CA2317505C (en) 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
DE19842578A1 (de) * 1998-09-17 2000-03-23 Max Delbrueck Centrum Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zum Herabsetzen thrombocytopenischer Nebenwirkungen von Cytostatika
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
AU774492B2 (en) 1999-07-22 2004-07-01 Celmed Oncology (Usa) Inc. Methods for treating therapy-resistant tumors
US20030212037A1 (en) * 2000-12-21 2003-11-13 Christopher Boyer Use of bvdu for inhibiting the growth of hyperproliferative cells
AU2451601A (en) * 1999-12-23 2001-07-03 Newbiotics, Inc. Use of bvdu for inhibiting the growth of hyperproliferative cells
EP1359921A4 (en) 2001-01-19 2006-09-06 Newbiotics Inc METHODS RELATING TO THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
DE10313035A1 (de) * 2003-03-24 2004-10-07 Resprotect Gmbh Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen
US20060269596A1 (en) * 2005-01-12 2006-11-30 Gary Liversidge Controlled release compositions comprising an acylanilide
HUP0600042A3 (en) * 2006-01-19 2012-12-28 Debreceni Egyetem New medical use of thiolated pyrimidine-mononucleotides and -nucleosides
DE102006037786A1 (de) * 2006-08-11 2008-03-20 Resprotect Gmbh Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090068286A1 (en) * 2007-09-11 2009-03-12 Resprotect, Gmbh Method of treating cancer by administration of 5-substituted nucleosides
EP2135601A1 (en) * 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilization of amorphous drugs using sponge-like carrier matrices
DE102008030091B4 (de) * 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1069096A (en) * 1962-11-23 1967-05-17 Ile De Rech S Scient Et Ind So New organic derivatives of nucleotides and method for their manufacture
GB1473148A (no) * 1974-09-16 1977-05-11
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
NL8700366A (nl) * 1987-02-13 1988-09-01 Stichting Rega V Z W Combinatie van fu met bvdu als middel tegen adenocarcinoom.
US5250296A (en) 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5831064A (en) 1996-07-25 1998-11-03 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpes virus (KSHV) interferon consensus sequence binding protein (ICSBP) and uses thereof
CA2317505C (en) 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents

Also Published As

Publication number Publication date
JPH11502515A (ja) 1999-03-02
KR100330602B1 (ko) 2002-08-22
NO973529L (no) 1997-10-01
EP0806956A1 (de) 1997-11-19
ES2180730T3 (es) 2003-02-16
US6589941B1 (en) 2003-07-08
NO315258B1 (no) 2003-08-11
DK0806956T3 (da) 2003-01-06
MX9705758A (es) 1997-10-31
ATE222765T1 (de) 2002-09-15
WO1996023506A1 (de) 1996-08-08
BR9607109A (pt) 1997-11-04
KR19980701862A (ko) 1998-06-25
DE59609590D1 (de) 2002-10-02
PT806956E (pt) 2003-01-31
EP0806956B1 (de) 2002-08-28

Similar Documents

Publication Publication Date Title
NO973529D0 (no) Anvendelse av 5'-substituerte nukleosider for å hemme resistensdannelse ved cytostatisk behandling og legemidler inneholdende slike nukleosider
EP2295063A8 (en) Compositions and the use thereof the treatment of mitochondrial diseases
CA2225808A1 (en) Silver-based pharmaceutical compositions
PL316080A1 (en) Pharmaceutic composition for sublingual or intrabuccal administration
ATE91233T1 (de) Antivirale pharmazeutische zusammensetzungen und ihrer verwendung.
CA2158475A1 (en) Composition and method for reducing toxicity of biologically-active factors
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
MY119375A (en) Treatment of tinnitus using neuroprotective agents
WO2000002549A3 (en) Composition for and method of treating neurological disorders
GR3022862T3 (en) Pharmaceutical composition for treating nicotine dependence.
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
CA2283399A1 (en) Pyridazinones as inhibitors of cyclooxygenase-2
BG104340A (en) 3'-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity
WO1993007866A3 (en) Compositions and methods for therapy and prevention of cancer, aids, and anemia
ES2180564T3 (es) 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina.
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
BE901301A (fr) 5-pyrimidine-carboxamides et thiocarboamides, ainsi que le traitement de la leucemie et des tumeurs avec ces substances.
CA2198580A1 (en) Combination therapy to treat osteoporosis
WO1999045909A3 (en) Use of nitrone compounds for the inhibition of angiogenesis
CA2322229A1 (en) Compositions comprising heparin and soluble tnf receptors for inhibition of tnf activity
EP1073436A4 (en) IMPROVED METHOD FOR ERADICATION OF HELICOBACTER PYLORI
AU3881095A (en) Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
GR3034142T3 (en) Composition for the treatment or prevention of herpes
CA2235951A1 (en) Novel uses of mammalian ctla-8 and related reagents

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees